Biomedicines (Jan 2024)

Successful Introduction of Benralizumab for Eosinophilic Ascites

  • Nabil Belfeki,
  • Nouha Ghriss,
  • Souheil Zayet,
  • Faten El Hedhili,
  • Cyrus Moini,
  • Guillaume Lefevre

DOI
https://doi.org/10.3390/biomedicines12010117
Journal volume & issue
Vol. 12, no. 1
p. 117

Abstract

Read online

Eosinophilic ascites is a rare disorder, reported in both adult and pediatric patients, characterized by high eosinophil counts in the peritoneal fluid. Eosinophilic ascites appears as a manifestation of various diseases such as parasitic and fungal infections, malignancy, and hypereosinophilic syndrome. It also represents an uncommon manifestation of eosinophilic gastroenteritis, usually treated with corticosteroids. We present the case of a 16-year-old woman with abdominal distention related to abundant ascites. Further work-up concluded that it was eosinophilic gastroenteritis complicated with eosinophilic ascites. The patient was on oral steroids for three weeks, but various abdominal relapses were observed, leading to the introduction of benralizumab, as a steroid-sparing therapy with a favorable outcome.

Keywords